Swedbank’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$107M Buy
754,282
+103,200
+16% +$16.6M 0.09% 157
2026
Q2
$110M Buy
651,082
+71,653
+12% +$10.6M 0.09% 156
2026
Q1
$76.3M Sell
579,429
-4,700
-0.8% -$624K 0.08% 181
2025
Q4
$82.8M Buy
584,129
+36,800
+7% +$5.33M 0.08% 174
2025
Q3
$76.8M Buy
547,329
+43,827
+9% +$5.94M 0.08% 178
2025
Q2
$63.3M Buy
503,502
+73,805
+17% +$8.46M 0.07% 196
2025
Q1
$47.5M Buy
429,697
+421,400
+5,079% +$53.4M 0.06% 213
2024
Q4
$1.13M Sell
8,297
-5,715
-41% -$707K ﹤0.01% 649
2024
Q3
$1.61M Hold
14,012
– – ﹤0.01% 627
2024
Q2
$1.93M Hold
14,012
– – ﹤0.01% 612
2024
Q1
$1.93M Buy
14,012
+6,768
+93% +$924K ﹤0.01% 608
2023
Q4
$954K Hold
7,244
– – ﹤0.01% 639
2023
Q3
$815K Hold
7,244
– – ﹤0.01% 632
2023
Q2
$683K Hold
7,244
– – ﹤0.01% 651
2023
Q1
$733K Hold
7,244
– – ﹤0.01% 652
2022
Q4
$865K Hold
7,244
– – ﹤0.01% 633
2022
Q3
$769K Hold
7,244
– – ﹤0.01% 654
2022
Q2
$706K Hold
7,244
– – ﹤0.01% 670
2022
Q1
$679K Hold
7,244
– – ﹤0.01% 700
2021
Q4
$613K Hold
7,244
– – ﹤0.01% 719
2021
Q3
$695K Hold
7,244
– – ﹤0.01% 706
2021
Q2
$705K Hold
7,244
– – ﹤0.01% 706
2021
Q1
$704K Buy
+7,244
New +$760K ﹤0.01% 699

Other funds holding NBIX

Swedbank's NBIX Position: Q3 2026 in Review

Swedbank increased its Neurocrine Biosciences (NBIX) stake by 16% in Q3 2026, buying an estimated $16.6M and bringing the position to 754,282 shares worth $107M. The position accounts for 0.09% of the portfolio, ranked #157.

Swedbank first reported a position in NBIX in Q1 2021 and has held it in 23 quarters since. The position peaked at $110M in Q2 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Swedbank held 754,282 shares of Neurocrine Biosciences worth $107M as of Q3 2026.
  • Swedbank bought 103,200 Neurocrine Biosciences shares in Q3 2026, an estimated $16.6M.
  • Neurocrine Biosciences made up 0.09% of Swedbank's portfolio in Q3 2026, its #157 holding.
  • Swedbank first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 23 quarters since.
  • Swedbank's Neurocrine Biosciences position peaked at $110M in Q2 2026.
  • 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Swedbank's 13F filing for Q3 2026, filed 27 Oct 2026.